Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diomed completes 1-to-25 reverse split stock:

This article was originally published in Clinica

Executive Summary

Diomed has reduced its number of outstanding shares from 365 million to 14.6 million, following the completion of a 1-to-25 reverse split stock. According to Diomed president and CEO, James Wylie, the move should bring the share price of the Andover, Massachusetts company share into a range that is more acceptable to both retail and institutional investors. Diomed's first quarter results for 2004 showed a 39% increase in revenues over Q1 2003. Revenues generated by its endovenous laser treatment (EVLT) for varicose veins increased 53% over the same period last year. Diomed owns exclusive rights to the patent covering its EVLT procedure which was cleared by the FDA in January 2002.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel